Roche reported that, in the first nine months, the Group generated sales growth of 2%, or 1% in francs, year-over-year to 47 billion Swiss francs. Sales of the Pharmaceuticals Division were at the same level as in the previous year, at 33.2 billion Swiss francs. The company noted that the newer medicines Ocrevus, Hemlibra, Evrysdi and Phesgo continued their strong growth during the period. Sales in the Diagnostics Division was up 6%, for the period.
from RTT - Earnings https://ift.tt/XIWe7MQ
via IFTTT
No comments:
Post a Comment